

CBNS Animal Imaging Workshop

Practical Session

– MSOT & OPTICAL –

TUMOUR LOCALISATION OF A FLUORESCENTLY LABELLED TARGETED NP

**Experimental
Description:**

A Cy5.5 labelled nanoparticle (~10-20 nm in diameter) with a targeting ligand for prostate cancer has been injected intravenously at a concentration of ~ 200 µg of dye per injection into two Balb/c nude mice bearing subcutaneously implanted tumours on the right flank of the mouse.

Key Questions

- How does the spatial resolution compare between the two instruments?
- What is the difference between the tumour localisation information observed with optical imaging and the MSOT?
- What type of information with regards to biodistribution can each technique give you?

– PET-CT –

LONGITUDINAL PET OF A ⁸⁹Zr LABELLED NP

**Experimental
Description:**

Images will be displayed and the data will be analysed for the full biodistribution and tumour localisation of a 7-day PET-CT study for a targeted NP labelled with ⁸⁹Zr. Image sets include a 60-minute dynamic PET, after 48 hours, and after 7 days. (The time point shown will be based on the session attended.)

Key Questions

- What anatomical information can be observed with CT?
- What biodistribution information can be determined?
- How do you validate your in vivo ROI data?

– PET-MRI –

DYNAMIC PET OF ^{18}F FDG AND SIMULTANEOUS Gd^{3+} CONTRAST ENHANCED MRI

Experimental Description: A Balb/c nude mouse bearing a subcutaneous PC3 tumour in the right flank will be injected intravenously with an ^{18}F FDG radiotracer and Magnevist, a chelated Gd^{3+} contrast enhancement agent to visualise the tumour and blood vessels in the mouse.

Key Questions

- What anatomical information can be observed with MRI?
- Where does the ^{18}F FDG go? Magnevist?
- What does the overlay of the two modalities show you?